Goodwin represented Kaleido Biosciences, which announced today that it has closed $101 million in an oversubscribed Series C financing.
Several new investors participated in the financing, along with Kaleido’s founder, Flagship Pioneering. Kaleido plans to use the proceeds from this financing to advance its pipeline, including conducting multiple clinical studies across several therapeutic areas, and to expand its platform.
Kaleido is a clinical-stage healthcare company leading the discovery and development of novel chemistries to drive functions of the microbiome organ to treat disease and improve human health. The company is advancing a robust pipeline of Microbiome Metabolic Therapies across a range of therapeutic areas, including rare genetic disorders. Kaleido’s unique discovery and development model is redefining traditional R&D, enabling product candidates to advance rapidly into the clinic, dramatically reducing time and cost.
The Goodwin team was led by partner Laurie Burlingame (Picture) and included partner Kingsley Taft, and associates Michael Cohen and Fabiola Valenzuela.
Law Firms: Goodwin Procter;
Clients: Kaleido Biosciences;